Max Masucci
Stock Analyst at TD Cowen
(0.21)
# 4,445
Out of 5,149 analysts
22
Total ratings
16.67%
Success rate
-30.77%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $39.27 | +83.35% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $20.17 | +23.95% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $93.30 | -43.19% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $75.46 | +25.89% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $5.87 | +206.64% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $15.50 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.06 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $2.41 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $0.76 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $4.44 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.24 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.34 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $129.56 | +262.77% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.43 | +628.86% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $103.37 | +40.27% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $39.27
Upside: +83.35%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $20.17
Upside: +23.95%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $93.30
Upside: -43.19%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $75.46
Upside: +25.89%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $5.87
Upside: +206.64%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $15.50
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.06
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.41
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.76
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.44
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.24
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.34
Upside: -
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $129.56
Upside: +262.77%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $3.43
Upside: +628.86%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $103.37
Upside: +40.27%